Immunic presents key vidofludimus calcium data at the actrims forum 2025, highlighting its potential in multiple sclerosis

– vidofludimus calcium's activation of nurr1 reduces neuronal loss and injury directly and indirectly by decreasing microglial activation s in preclinical models – – top-line data from phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis expected in april – new york , feb. 26, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data on its lead asset, nuclear receptor-related 1 (nurr1) activator, vidofludimus calcium (imu-838), in two poster presentations at the americas committee for treatment and research in multiple sclerosis (actrims) forum 2025, taking place from february 27 to march 1, in west palm beach, florida. "having two poster presentations on vidofludimus calcium at the prestigious actrims forum highlights the unique importance of our drug candidate and its promise as a potential new treatment option for multiple sclerosis (ms)," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking